Key Highlights

● Third quarter adjusted earnings were $4.69 per share, up from $2.92 a year earlier.

● Medical care ratio improved to 88.4% from 89.9%, aided by roughly $610 million reserve benefit.

● Management raised full-year adjusted earnings guidance to at least $20.50 per share.

● Medical membership slipped to about 48.3 million, with Medicare Advantage down roughly 935,000 this year.

UnitedHealth Group (NYSE:UNH), the largest U.S. health insurer by revenue and a major name in the S&P 500, has stayed in the market conversation since its third quarter report on October 13. According to the earnings release furnished to the Securities and Exchange Commission, adjusted earnings reached $4.69 per diluted share, compared with $2.92 a year earlier, while earnings from operations rose to about $6.6 billion.

The company also raised its full-year guidance, now calling for adjusted earnings of at least $20.50 per share. Behind the headline, though, the report showed a business that is smaller in membership and revenue terms than a year ago, which is why the quarter is being read as a repair story and not a simple growth story.

What Did UnitedHealth Group Report for the Third Quarter on October 13?

UnitedHealth Group released third quarter results on October 13 and furnished the full earnings release to the Securities and Exchange Commission. Revenue came to about $112.7 billion, a touch below the $113 billion reported in the same quarter of last year. Over the first nine months of the year, revenue totaled about $336 billion.

Earnings from operations climbed to about $6.6 billion from roughly $4.3 billion a year earlier. Net earnings attributable to common stock owners reached about $4.1 billion, up from roughly $2.35 billion, and the net margin widened to 3.6% from 2.1%.

On a per-share basis, diluted earnings were $4.56, versus $2.59 in the comparison quarter. Adjusted earnings, which exclude amortization of acquired intangibles and other items the company identifies, were $4.69, versus $2.92. For the nine months, adjusted earnings reached $18.30 per share.

The company's chief executive, Stephen Hemsley, said in the release that the quarter reflected discipline and execution across the organization.

How Did the Medical Care Ratio at UnitedHealth Group Move, and Why Does It Matter?

The medical care ratio, which measures the share of premium revenue spent on patient care, improved to 88.4% from 89.9% in the same quarter last year. For an insurer, a movement of that size is large, because each percentage point on a premium base of this scale represents a very large amount of money.

The release states that the ratio included about $610 million of favorable development of prior-period reserves. That detail matters for interpretation. Favorable reserve development means that medical costs for earlier periods turned out lower than the company had estimated, and the benefit is booked in the current quarter. It is real accounting earnings, but it is not a measure of how current-period claims are trending.

The operating cost ratio also improved, to 12.8% from 13.5%, indicating that administrative spending fell relative to revenue. Together, the two ratios explain most of the jump in operating earnings.

Market participants typically watch the medical care ratio because insurers set premiums months in advance and then absorb whatever utilization arrives. Elevated use of outpatient procedures, specialty drugs and behavioral health services pressured the industry in recent periods, so a lower ratio is read as evidence that repricing and benefit changes are working. Whether the pace of improvement can continue without the reserve benefit is a question the company did not fully answer in the release.

What Does UnitedHealth Group's Raised Earnings Guidance for the Year Actually Say?

In the release, the company lifted its full-year guidance for 2026. Diluted earnings per share are now expected to be at least $19.50, and adjusted earnings per share at least $20.50. The phrase at least signals a floor set by management, not a ceiling, and it is guidance and not a reported result.

Because nine-month adjusted earnings already stand at $18.30, the raised floor implies a fourth quarter that is substantially smaller than the third. That arithmetic reflects normal seasonality in insurance, where medical costs generally rise late in the year as members reach deductibles, and it also reflects the one-time nature of some third quarter benefits.

The change in guidance came with a set of operating commitments laid out in the same document. The company said it is aiming to eliminate about 30% of its current prior authorization volume by the end of this year, and that it will pass through manufacturer drug rebate discounts to clients in full by the start of 2028. It also said earnings on individual Affordable Care Act plans would be eliminated and rebated to roughly 1 million members in 2026.

Those commitments are best read as part of a broader effort to respond to public and political scrutiny of the insurer. They carry costs and may reduce certain revenue streams, and the company has not detailed every financial effect.

Why Is UnitedHealthcare Membership Shrinking Even as Earnings Recover?

UnitedHealthcare, the insurance arm, reported revenue of about $86.3 billion, down from about $87.1 billion, while earnings from operations rose to about $2.8 billion from about $1.8 billion. The operating margin was 3.3%.

Medical membership ended September at about 48.3 million, compared with about 48.5 million in June and about 50.1 million a year earlier. Commercial plans covered about 29.8 million people, Medicare Advantage about 7.6 million, Medicaid about 6.7 million, and Medicare Supplement about 4.2 million.

The filing states that Medicare Advantage enrollment has fallen by about 935,000 people since the end of last year. In the third quarter alone, the employer and individual business lost about 165,000 people and the community and state business lost about 85,000.

Shrinking enrollment is partly a choice. Insurers across the industry have exited counties, trimmed benefits and raised prices in loss-making plans in order to restore margins, and the resulting loss of members is the cost of that repair. The open question is how much of the loss is intended pruning and how much reflects customers moving to competitors, and the release does not quantify that split.

How Did the Optum Units Contribute to UnitedHealth Group's Third Quarter?

Optum, the health services group, reported revenue of about $66.9 billion versus about $69.2 billion a year earlier, with earnings from operations of about $3.7 billion versus about $2.5 billion. The operating margin was 5.6%.

Optum Health, which operates care delivery and value-based care arrangements, posted revenue of about $22.9 billion, down about 10%, but earnings from operations rose to about $735 million from only about $41 million a year earlier. The margin was 3.2%. That swing is among the most notable lines in the report, since Optum Health was a source of pressure when the company reset its expectations earlier.

Optum Insight, the data and technology unit, generated revenue of about $5.5 billion, up 3%, with earnings from operations of about $1.3 billion and a margin of 23.4%. Optum Rx, the pharmacy benefit business, had revenue of about $39.9 billion and earnings from operations of about $1.7 billion.

One detail stands out in the pharmacy unit. Adjusted prescriptions fell to about 393 million from about 414 million, which the company tied to membership declines at UnitedHealthcare and at other customers. Lower volume in the pharmacy business is the mirror image of lower insurance membership.

What Do Cash Flow, Debt and Share Retirement Show About UnitedHealth Group's Balance Sheet?

Cash generation was solid in the quarter. Operating cash flow was about $5.1 billion, or roughly 1.2 times net earnings, and nine-month operating cash flow reached about $25.1 billion. Cash conversion above one times net earnings is generally read as a sign that reported earnings are backed by actual cash.

The debt-to-capital ratio edged up to 41.7% from 41.2% at the end of the second quarter. The company said it is aiming to bring that ratio to about 40% by year-end, which implies that debt reduction is a stated priority for the coming months.

Capital was also distributed to stock owners through two channels. Year to date, the company spent about $5 billion on its share retirement program and about $6.2 billion on dividends, according to the release. For a company of this size, those amounts are meaningful, although they compete with the stated goal of lowering leverage.

The combination of rising leverage, a large dividend, and an active share retirement program is worth watching. If medical costs surprise to the upside, the cushion provided by cash flow would be tested first, and the company would have to balance its commitments against the ratio goal it has publicly set.

What Challenges Does UnitedHealth Group Still Face After the Improved Quarter?

Several uncertainties remain. First, the reserve development benefit of roughly $610 million flattered the medical care ratio, and the underlying trend may be less favorable. Second, membership is shrinking in the segments that provide the largest premium base, and a smaller base can limit revenue growth in 2027.

Third, government programs remain a swing factor. Medicare Advantage payment rates, member-scoring methods and audit activity are set or enforced by federal agencies, and the company has repeatedly said that such decisions affect its plan design. Medicaid redeterminations and state budget pressures add another layer of unpredictability for the community and state business.

Fourth, the company is making public commitments that may cost money, from reducing prior authorization to passing through drug rebates and rebating individual plan earnings. These moves could improve trust among patients, doctors and lawmakers, but they may also trim margins.

Finally, the pharmacy benefit business operates under regulatory and legislative scrutiny over how rebates and fees are structured. The company's pledge to pass through all manufacturer rebate discounts by the start of 2028 is a response to that scrutiny, and its financial effect will only become clear as the transition proceeds.

How Does UnitedHealth Group Compare With Other Managed Care Companies This Season?

Managed care companies have spent the past two years working through higher utilization, tighter government payment, and rising specialty drug costs. UnitedHealth Group's third quarter fits into that shared story but also stands apart in scale, because it combines the nation's largest commercial and Medicare Advantage insurance book with a very large physician, data and pharmacy services arm.

That structure has advantages and complications. Optum's services provide diversification and data that can help manage costs, but they also create conflict-of-interest questions that lawmakers and regulators have raised. Competitors with narrower insurance-only models face fewer of those questions, while lacking the same breadth.

In the third quarter, the company's medical care ratio of 88.4% and operating margin of 3.3% at UnitedHealthcare show recovery, but both are still modest by the standards of the company's history before the recent stress. Peers reporting this season have also described a mix of stabilizing costs and ongoing caution.

Sector context matters because the healthcare industry is exposed to the same federal decisions. A change in Medicare payment rules or drug pricing law would not affect one insurer in isolation, and results across the group can move together on such news.

What Should Readers Watch Next at UnitedHealth Group Beyond the Third Quarter Report?

The next scheduled milestones include the fourth quarter report, which the company typically issues in January, and the annual Medicare Advantage enrollment period that opens in the fall. Enrollment trends in that window will show whether the benefit and price changes made for next year attract or deter members.

Other items to follow are the progress toward the 40% debt-to-capital goal, the pace of the share retirement program relative to debt paydown, and any further disclosure about the size of favorable reserve development. A third quarter in which reserve benefits played a large role makes the underlying trend in the coming quarters more important.

Regulatory events to follow include federal payment notices, congressional hearings on pharmacy benefit managers, and any updates on inquiries that the company has disclosed in earlier filings. These can arrive without warning and sometimes outweigh quarterly operating results.